An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023

An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023

Abstract Background We present the study rationale and design of the JGOG3023 study, an open-label, parallel-arm, randomized, phase II trial that aimed to assess the efficacy and safety of chemotherapy with or without bevacizumab in patients with platinum-resistant recurrent epithelial ovarian, fall...

Full description

Bibliographic Details
Main Authors: Tadahiro Shoji, Shinichi Komiyama, Junzo Kigawa, Hiroshi Tanabe, Kazuyoshi Kato, Hiroaki Itamochi, Hiroyuki Fujiwara, Shoji Kamiura, Tetsutaro Hamano, Toru Sugiyama, for the Japanese Gynecologic Oncology Group
Format: Article
Language:English
Published: BMC 2018-07-01
Series:BMC Cancer
Subjects:
Bevacizumab
Platinum-resistant ovarian cancer
Ovarian cancer
Chemotherapy
Progression-free survival
Beyond progression
Online Access:http://link.springer.com/article/10.1186/s12885-018-4505-4

Internet

http://link.springer.com/article/10.1186/s12885-018-4505-4

Similar Items